Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
The three primary retatrutide injection sites Clinical trials for retatrutide specified three approved injection sites: the abdomen, the anterior thigh, and the posterior upper arm
Portion-controlled, high-protein meals like Clean Eatz Kitchen's options (25-35g protein per serving) make it easy to meet nutritional needs without meal planning stress
In regions where Zepbound is covered, Kaiser requires extensive step therapy
It exists
While muscle loss is standard with any diet or weight-loss regimen, loss of muscle on GLP-1s can be more dramatic, Ahmed says, causing what's been dubbed "Ozempic face," a bonier, looser-skinned look, where the muscle loss is particularly noticeable